摘要:
The present invention relates to compounds of formula I wherein R1, R2 and R3 are defined herein, their pharmaceutically acceptable salts, enantiomeric forms, diastereoisomers and racemates, the preparation of the above compounds, medicaments containing them and their manufacture, as well as the use of the above compounds in the control or prevention of illnesses such as cancer.
摘要:
One embodiment of the present invention provides a system that accommodates different clock frequencies in an EPON. The system receives a signal from the OLT at the ONU and derives an OLT clock. The system also maintains a local clock. The system further receives from the OLT an assignment for an upstream transmission window, during which the ONU can transmit an upstream data burst to the OLT based on the local clock. The system adjusts the number of bits of the data burst without affecting the payload data carried in the data burst, thereby allowing the data burst to fit properly within the upstream transmission window and compensating for frequency differences between the local clock and the OLT clock. The system transmits the data burst based on the local clock in the upstream transmission window.
摘要:
Compounds of formula I their pharmaceutically acceptable salts, enantiomeric forms, diastereoisomers and racemates are disclosed. Also disclosed are methods for the preparation of the above-mentioned compounds, pharmaceutical compositions containing them, as well as the use of the above-mentioned compounds in the treatment, control or prevention of illnesses such as cancer.
摘要:
One embodiment of the present invention provides a system for forwarding packets in an Ethernet passive optical network (EPON) which includes a central node and at least one remote node. During operation, the system associates a logical link identifier (LLID) to a logical link between the central node and a remote node, wherein the logical link corresponds to a priority level based on a certain service level agreement (SLA). After receiving a packet to be forwarded to a remote node, the system then determines the value of one or more fields within the packet which is used to indicate a priority level for the packet. Subsequently, the system assigns an LLID to the packet based on the value of the one or more fields, thereby facilitating differentiated service qualities within the EPON.
摘要:
One embodiment of the present invention provides a system that facilitates dynamic allocation of upstream bandwidth in a passive optical network which includes a central node and at least one remote node. Each remote node is coupled to at least one logical entity, which corresponds to a device or a user, that transmits upstream data to the central node and receives downstream data from the central node. The central node is coupled to an external network outside of the passive optical network through a shared out-going uplink.
摘要:
The present invention relates to compounds of formula I wherein R1, R2 and R3 are defined herein, their pharmaceutically acceptable salts, enantiomeric forms, diastereoisomers and racemates, the preparation of the above compounds, medicaments containing them and their manufacture, as well as the use of the above compounds in the control or prevention of illnesses such as cancer.
摘要:
A compound of formula (I): or a salt, solvate and chemically protected form thereof, wherein: R5is an optionally substituted C5-20 aryl or C4-20 alkyl group; A is selected from the group consisting of: wherein X and Y are selected from the group consisiting of: O and CR3; S and CR3; NH and CR3; NH and N; O and N; S and N; N and S; and N and O., and where the dotted lines indicate a double bond in the appropriate location, and where Q is either N or CH; R3 is selected from H, F, Cl and optionally substituted C1-4 alkyl, C1-4 alkoxy, C5-7 aryl and C5-7 aryl-C1-4 alkyl groups; R4 is selected from H, F, Cl and optionally substituted C1-4 alkyl, C1-4 alkoxy, C5-7 aryl and C5-7 aryl-C1-4 alkyl groups; R6 is selected from H, F, Cl and optionally substituted C1-4 alkyl, C1-4 alkoxy, C5-7 aryl and C5-7 aryl-C1-4 alkyl groups; D is selected from: B is selected from the group consisting of: where RN′ is selected from H and C1-4 alkyl; where one of RP3 and RP4 is —Cm alkylene-R2 and the other of RP3 and RP4 is H, m and n can be 0 or 1, and m+n=1 or 2; and additionally when RP3 is —Cm alkylene-R2, m can also be 2 or 3, and m+n=1, 2, 3 or 4, and when R2 is tetrazol-5-yl, m+n may be 0; or where one of RP3 and RP4 is —O—CH2—R2, and the other of RP3 and RP4 is H, n is 0; RN is H or optionally substituted C1-4 alkyl; R2 is either: —CO2H (carboxy); —CONH2; —CH2-OH; or tetrazol-5-yl.
摘要:
One embodiment of the present invention provides a system that performs packets switching in a passive optical network which includes a central node and at least one remote node. After receiving a packet, the system obtains a first set of results by performing a first lookup based on a first set of values derived from the packet. The system also obtains a second set of results by performing a second lookup based on a second set of values derived from the packet. Next, the system merges the first set of results and the second set of results, and produces a merged value. The system then obtains a subsequent result by performing a subsequent lookup with the merged value. If the packet is a downstream packet, the system derives a logical identifier corresponding to one or more remote nodes from the subsequent result. The system then incorporates the logical identifier into the packet and transmits the packet to one or more remote nodes.
摘要:
The invention provides anti-apoptotic compositions lysophosphatidic acids and methods for making and using the compositions. Such compositions can also contain LPA potentiating agents, including proteins, lipid membrane structures and polymers such as polyethylene glycols. The compositions can additionally contain other pharmaceutically effective agents such as drugs, antibiotics, wound healing agents and antioxidants.